Objective: To assess the long-term neurodevelopment of children exposed in utero to selective serotonin reuptake inhibitors (SSRIs) that developed a neonatal abstinence syndrome (NAS).
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are commonly used during pregnancy, mainly for the treatment of depressive disorders. Because SSRI use during pregnancy is perceived as having a favorable risk:benefit ratio, 1,2 the use of these drugs during pregnancy has increased over the past decade 3 and they are prescribed in 2.3 to 6.2% of pregnancies. [3] [4] [5] Short-term adverse outcomes occur in up to 30% of infants exposed in utero to SSRIs. [6] [7] [8] SSRI-related symptoms have been attributed to both direct drug effects 9 and to a withdrawal syndrome. 8 Short-term effects include disruptions in a wide range of neurobehavioral outcomes. 8, 10 Neonatal neurological symptoms include signs of both central nervous system excitation (increased motor activity, increased spontaneous startles and arousals, restlessness, tremors, hypertonicity, high pitched cry, seizures) and depression (lethargy, weak cry, weak sucking, aphonia), autonomic symptoms (decreased heart rate variability, temperature instability, mottling, sweating), decreased changes in behavioral states and abnormal sleep organization. 8, 10 Additional neonatal symptoms mainly affect the gastrointestinal system (diarrhea, poor feeding, vomiting) and the respiratory system (tachypnea, dyspnea, persistent pulmonary hypertension). 2, 9 Despite the widespread use of SSRIs during pregnancy and the plethora of neonatal symptoms related to their use, there is relatively limited information with regard to long-term outcome of exposed infants. In rodents, increased extracellular serotonin levels during the perinatal period can cause subtle changes in brain circuitry and maladaptive behaviors, such as increased anxiety, aggression or depression, that are maintained into adulthood. These effects are thought to be mediated by excessive activation of serotonin receptors. 11 In human beings, SSRI exposure during pregnancy has shown a possible relationship to prolonged behavioral changes. 10, 12 Oberlander et al. 13 have shown that newborns exposed in utero to SSRIs exhibit prolonged decreased reactivity to pain as evident by blunted facial-action responses to pain at the age of 2 months. Long-term studies in preschool children have shown that cognitive and language development are not affected by SSRI exposure during pregnancy.
12,14,15 SSRI exposure also does not seem to affect internalizing behaviors. 16 On the other hand, Casper et al. 15 showed that children exposed to SSRIs during pregnancy scored lower on the Bayley psychomotor development indexes and on the motor quality factor of the Bayley Behavioral Rating Scale than unexposed children. Zeskind and Stephens 10 reported that SSRI-exposed infants had abnormal neurobehavioral outcomes, including fewer changes in behavioral state, abnormal sleep patterns and increased motor activity. In contrast to the studies by Zeskind and Stephens 10 and Casper et al., 15 the study by Nulman et al. 14 did not find any effect of SSRIs on behavior or motor activity. Oberlander et al. 12 have reported an increase in externalizing behaviors at the age of 4 years; however, this was accounted for mostly by maternal depressed mood.
Although it is biologically plausible that in utero SSRI exposure effects the neurobehavioral development of children, this has not been consistently established. Furthermore, the relationship between neonatal withdrawal symptoms and long-term outcome is unknown. The aim of this study was to prospectively assess the long-term neurodevelopment of children exposed during pregnancy to SSRIs that were initially screened after birth for signs of a neonatal abstinence syndrome (NAS) using the standardized Finnegan score. 17 Two groups of children were evaluated and compared, those who had neonatal withdrawal symptoms (Finnegan score X4) and those who did not (Finnegan score 0 to 3).
Methods
This study prospectively followed a cohort of children exposed in utero to SSRIs described in part by Levinson-Castiel et al. 8 The cohort was initially evaluated during the period January 2002 through December 2006 by the Neonatal Department at Rabin Medical Center. Children were re-evaluated at the age of 2 to 6 years by the developmental team of the Neurology Clinic at Schneider Children's Medical Center of Israel, which is a university-affiliated, tertiary-care center adjacent to Rabin Medical Center. The infants were initially identified from the delivery room records as they arrived at the nursery or from a medical history form completed by all mothers on admittance to the nursery. Excluded were infants with major congenital birth defects affecting development, congenital syndromes or chromosomal abnormalities, infants born following multiple pregnancy, preterm infants (<36 weeks gestation) and infants exposed to additional teratogenic drugs. Maternal intake of SSRIs during pregnancy, including fluoxetine, paroxetine, citalopram, sertraline, fluvoxamine and the serotonin-noradrenaline reuptake inhibitor venlafaxine, was recorded in each case. All full-term infants who had prolonged exposure to SSRIs during the entire pregnancy or at least the third trimester were eligible for the study. Exposed infants were followed by a standard protocol including use of the Finnegan score, which is an objective method used to monitor onset, progression and improvement of neonatal abstinence symptoms in passively exposed neonates. The score rates 21 symptoms most commonly seen in drug-exposed neonates, and is also used to assess the need for pharmacological intervention and the response to treatment. Higher scores represent more severe abstinence symptoms, with a consequent risk of increased morbidity. A severe withdrawal syndrome was defined as a Finnegan score of 8 or above on one or more assessments, and mild NAS was defined as a score of 4 to 7 on at least two examinations. Following a minimum observation period of 48 h, infants were discharged from the nursery if their Finnegan scores had normalized and there were no additional medical issues requiring hospitalization.
Parents of children exposed in utero to SSRIs were requested to participate in a developmental evaluation of their child. Children for whom consent was obtained were divided into two groups: those who had a mild to severe NAS and those who were asymptomatic after birth. The evaluation included age appropriate tests administered by an expert developmental pediatrician and by a child psychologist, who were blinded as to the presence of an NAS after birth as well as to what medication the children were exposed to. Medical history and demographic information were obtained from the children's parents. Head circumference percentile was determined using standard head circumference curves. 18 Each child underwent a standard physical and neurodevelopmental examination. In our Child Development Center, our standard neurodevelopmental assessment performed by a developmental pediatrician utilizes the Denver Developmental Screening Test II (DDST-II), which is suitable for screening and general pediatric developmental testing of children from birth to 6 years of age, with correlation from 0.86 to 0.97 with individual measures of IQ or development. 19 The DDST-II provides scores in four areas of functioning: Gross Motor, Fine Motor-Adaptive, Language and Personal-Social. The DDST-II includes areas not represented (gross motor and personal-social) or under-represented (fine motor-adaptive) in the standard intelligence tests administered by a developmental psychologist. A developmental age (DA) was derived from the DDST-II within each sector of the test, along with a mean Denver test result. DAs were divided by the chronological age, with ratio scores constituting the dependent variables. Ratio scores for each of the four streams of development examined by the test were considered normal if they were within one standard deviation (s.d.) of norm, whereas those exceeding 1 s.d. were considered abnormal. To complement and increase the accuracy of developmental evaluation, a single additional intelligence test was performed by a child psychologist using the Wechsler Preschool and Primary Scale of Intelligence-II, the Stanford-Binet Intelligence Scales or the Bayley Scale of Infant Development-II as age appropriate. Attention deficit hyperactivity disorder was assessed using an abbreviated Connor's scale for children age 3 and above. The Hamilton anxiety score 20 was completed by the infant's mothers during their child's follow-up visit. This is a validated questionnaire for assessment of anxiety that has previously been used to assess anxiety in SSRI-treated mothers, 12 and that also provides a limited assessment 
Statistical analysis
Two groups of children were compared: Group 1 included children who exhibited NAS after birth and Group 2 included children who did not exhibit symptoms compatible with NAS. Continuous variables were compared using the Student's t-test, whereas discrete variables were compared using Pearson's w 2 test or Fisher's exact test, as appropriate. Correlation was assessed using the Spearman correlation test. Stepwise logistic regression was performed using those variables found to be significant in the univariate analyses. A P-value of p0.05 was considered statistically significant. The data were analyzed using BMDP Statistical Software (1993, Chief Editor: WJ Dixon, University of California Press, Los Angeles, CA, USA).
Results
During the initial study period, we identified 180 mothers who reported using SSRIs during pregnancy. Excluded were 12 mothers who took additional teratogenic drugs, nine twin pregnancies, eight premature deliveries and one infant with major congenital anomalies (cleft palate and ventriculo-septal defect), leaving 150 mothers eligible for our study. Consent was obtained for 82 of 150 infants (55%). Developmental evaluation was performed between January 2007 and December 2009. Thirty of 34 infants (88.3%) who had NAS participated in the study, whereas only 52 of 116 infants (44.8%) without NAS were included. There was no statistically significant differences in the mean Finnegan scores of infants with NAS who participated vs those who did not (5.7 ± 2.3 vs 6.4±2.6), as well as those without NAS who participated vs those who did not (1.5 ± 1.3 vs 1.7 ± 1.4). Maternal characteristics of infants with vs without NAS following in utero exposure to SSRIs are described in Table 1 . The socioeconomic status, maternal education and use of SSRIs during pregnancy were similar in both groups; however, mothers of infants who had NAS tended to be older (34.5 vs 32.2 years, P ¼ 0.03). The characteristics at birth of infants with vs without NAS following in utero exposure to SSRIs are presented in Table 2 . Comparison of infant measures at birth showed no significant differences; however, it is of note that for the combined cohort, 11 of 82 infants (13%) had a head circumference p3rd percentile. At follow-up exam, the mean maternal results on the Hamilton Anxiety Scale for children who had vs who did not have NAS did not differ statistically (16.2±6.4 vs 14.0±5.8, P ¼ 0.23). The results of neurological and cognitive evaluation of children following in utero exposure to SSRIs are presented in Table 3 . Fifty-two children underwent intelligence testing, including 42 children who had the Bayley Scale of Infant Development-II test (19 in the NAS and 23 in the no-NAS groups), six children who had the Stanford-Binet Intelligence Scale test (three in each groups) and four children who had the Wechsler Preschool and Primary Scale of Intelligence II test (two in each group). Children who had NAS vs those who did not, had a similar rate of neurological abnormalities on exam (10 vs 6%, P ¼ 0.66); however, there was a trend towards smaller head circumference among former NAS babies (20 vs 6%, P ¼ 0.068). The only neurological abnormality detected was hypotonia. In children who had NAS vs those who did not, the mean overall developmental results of the DDST-II test did not differ statistically (95.7±9.9 vs 98.9 ± 11.4, P ¼ 0.21). However, children who had NAS were more likely to have abnormal results on the social component of the DDST-II (47 vs 19%, P ¼ 0.009). In the subgroup of children who underwent a Connors test, there were no differences between children who had NAS vs those who did not (1 of 12 vs 3 of 18, P ¼ 0.63). Both study groups did not differ statistically in their mean intelligence test results (Wechsler Preschool and Primary Scale of Intelligence II, Stanford-Binet Intelligence Scale or Bayley Scale of Infant Development-II) (100.5±14.6 vs 106.9±14.0, P ¼ 0.12). The results of the DDST-II and those derived from the additional intelligence tests (Wechsler Preschool and Primary Scale Discussion SSRI use during pregnancy is now common; 3-5 however, considering the widespread use of these drugs, surprisingly few studies have assessed the long-term effects on exposed infants. 12,14 -16,21 Furthermore, the relationship between NAS and adverse outcome has not been previously investigated. To the best of our knowledge, our study is the first comparing long-term outcome of prenatally SSRI-exposed infants with NAS to those who did not develop NAS. In this study, we have found that children diagnosed at birth with NAS do not show evidence of impaired intelligence; however, these children frequently exhibit abnormalities in behavior and social adaptability.
Neurodevelopment studies of children exposed in utero to SSRIs have generally reported child intelligence to be unaffected by drug exposure. Nulman et al. 14, 21 showed that exposure during pregnancy to fluoxetine does not affect global IQ or language development. Similarly, Oberlander et al. 12 did not find any significant difference in intelligence scores at the age of 4 years between SSRI-exposed and non-exposed children. Casper et al. 15 found that pregnancy exposure to SSRIs had no effect on the Bayley mental developmental indices; however, the Bayley psychomotor development indices and the motor quality factor of the Bayley Behavioral Rating Scale were lower in exposed vs unexposed children, indicating that SSRI exposure may have subtle effects on motor development. In this study, we have found that the mean intelligence assessment of all SSRI-exposed infants was within the range expected in the normal population and that the mean intelligence test results of infants who had NAS did not differ from those who did not. These results provide further evidence that SSRI exposure during pregnancy does not have any measurable Outcome after in utero exposure to SSRIs G Klinger et al effect on intelligence, and that even when neonatal withdrawal symptoms are severe, normal intelligence can be expected. The possible long-term behavioral effects of SSRIs on children have been reported previously. 12, [14] [15] [16] 21 Maternal disease, including depression and anxiety, has been shown to affect adversely specific infant outcomes, including social engagement, immature regulatory behaviors and negative emotionality. 22, 23 Therefore, assessment of maternal mood and/or anxiety has been used to correct for maternal disease while assessing the effect of prenatal exposure to SSRIs on the infant or young child. Nulman et al. 14, 21 in two different studies failed to show any effect of exposure to fluoxetine on behavioral development in preschool children. Misri et al. 16 looked at internalizing behaviors (for example, depression, anxiety, withdrawal) and did not find prenatal SSRI exposure to be associated with abnormalities in these behaviors. Oberlander et al. 7 previously reported poor neonatal adaptation to be related with increased umbilical cord drug levels. Oberlander et al. 12 analyzed externalizing behaviors (attention, aggression, hyperactivity, defiance) in 4-year olds and their relationship to prenatal exposure and neonatal symptoms. Increased externalizing behaviors were associated with increased umbilical cord drug levels; however, when controlled for maternal depressed mood at the time of follow-up, the drug levels accounted for only 11.2% of behavioral outcomes. Increased aggressiveness was associated with a history of poor neonatal adaptation, even when controlled for parental stress. In the present study we corrected for the effect of maternal anxiety on the child using the Hamilton Anxiety Scale, which has been previously employed for this purpose. 12 We have found that in children who had NAS compared with those who did not, there was a threefold risk for abnormalities on the social component of the DDST-II. This component measures behavior and social adaptability and includes activities such as independence in self-help skills (activities of daily living), social imitative play and the ability to clearly communicate personal needs and desires. These activities are closely related to the externalizing behaviors reported by Oberlander et al. 12 The association between NAS, as measured by the Finnegan score, and abnormalities on the social component of the DDST-II represent the long-term effects of prolonged exposure to SSRIs on the serotonergic pathways of the central nervous system. The individual vulnerability of the brain to SSRIs likely explains why some infants develop NAS and some do not, and also explains why umbilical cord drug levels account for only a small fraction of behavior abnormalities. 12 Gene polymorphisms such as that of the serotonin transporter (5-HTT) have been shown to predict response to SSRI treatment in adults 24 and may identify patients at risk for developing adverse drug reactions. 25 In newborns prenatally exposed to SSRIs, the severity of neonatal symptoms has been associated with genetic polymorphisms in the cytochrome P450, monoamine oxidase A and catechol-O-methyltransferase enzymes. 26 Thus, it is seems that genetic predisposition to the effects of SSRIs determines the severity of neonatal symptoms following in utero exposure to SSRIs. Identification of genetic markers associated with adverse response to SSRIs may in the future enable treatment with drugs that are less likely to cause adverse outcomes. 27 The relationship between small head circumference at birth and maternal disease with or without prenatal SSRI exposure is controversial. Maternal prenatal psychological stress has been associated with impaired fetal head growth. 28 However, Hosseini et al. 29 did not find any relationship between head circumference at birth and anxiety. Maternal depression has also been associated with a smaller head circumference at birth. 30 In contrast, Nulman et al.
14 did not find any association between maternal depression treated with SSRIs during pregnancy and head circumference. Davidson et al. 31 reported a trend towards small head circumference at birth in infants exposed in utero to SSRIs. This article described a small cohort of children included in our study. In contrast to this report, others have failed to find any association between infant head circumference and in utero exposure to SSRIs. 14, 32 In this study, head circumference p3rd percentile was observed more frequently than expected in the general population for both study groups. At the time of follow-up exam, there was a trend towards small head circumference in the NAS group. Owing to the study design, we cannot determine whether the trend towards small head circumference was related to the NAS or was the result of maternal disease. Furthermore, the importance of this trend in unknown, as cognitive ability was not affected.
Our study is the first long-term study to prospectively follow infants who were diagnosed as having an NAS using the standardized Finnegan score. A relatively large cohort was studied using validated tests. However, some study limitations must be acknowledged. Maternal assessment did not include maternal psychological evaluation; thus, we could only partially control for the effects of maternal psychopathology. In addition, owing to the study design, maternal anxiety was assessed at the time of followup and may not accurately reflect anxiety after birth. Secondly, not all parents agreed to testing. Mothers of children who did not have abstinence symptoms were less likely to agree to take part in the study, resulting in a recruitment rate of less than 50%, and possibly introducing a bias. Thirdly, child evaluation was performed before school age; thus, subtle developmental problems may not have been recognized. Owing to the age range of the children examined, a single intelligence test could not be used. Finally, the assessment of social-behavioral ability was based on one of the DDST-II components and does not have the same strength as a specific diagnostic test.
In conclusion, this study has found no evidence suggesting that cognitive ability is influenced by prenatal exposure to SSRIs. Infants exposed to SSRIs who developed NAS are at an increased risk for social-behavioral abnormalities compared with those who did not develop NAS. The study results are reassuring to mothers treated with SSRIs because even symptomatic newborns have normal intelligence scores. However, the increased incidence of small head circumference requires further investigation. Psychological evaluation and follow-up may be indicated in children who exhibit significant neonatal abstinence symptoms.
